Vertex Pharma

News

Vertex's bid to expand beyond cystic fibrosis has taken a big step forward with phase 3 data for povetacicept in severe kidney disorder IgAN.

News

Shares in Vertex Pharma have come under pressure after one of its non-opioid pain candidates failed to move the needle in a mid-stage trial.

News

Vertex has won NICE's backing for a new cystic fibrosis therapy, Alyftrek, that could be an option for 89% of NHS patients with the genetic disorder.

News

A cell therapy developed by Vertex Pharma has allowed 10 of 12 patients with type 1 diabetes to control their blood sugar without insulin.

News

Italfarmaco's oral HDAC inhibitor Duvyzat has been recommended for approval in the EU as a treatment for Duchenne muscular dystrophy (DMD).

News

Latigo has tapped into investor interest in pain relief medicines with new, non-opioid mechanisms of action, raising $150 million in a Series B.